| Heather Gridley, MD | |
|
7455 W Washington Ave Ste 301, Las Vegas, NV 89128-4340 | |
| (877) 562-5227 | |
| Not Available |
| Full Name | Heather Gridley |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 9 Years |
| Location | 7455 W Washington Ave Ste 301, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285019612 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 21722 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mountainview Hospital | Las vegas, NV | Hospital |
| Southern Hills Hospital And Medical Center | Las vegas, NV | Hospital |
| Centennial Hills Hospital Medical Center | Las vegas, NV | Hospital |
| Havasu Regional Medical Center | Lake havasu city, AZ | Hospital |
| Mesa View Regional Hospital | Mesquite, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Laboratory Medicine Consultants Ltd | 4183617533 | 27 |
| Laboratory Medicine Consultants Ltd | 4183617533 | 27 |
News Archive
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.
InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax's activities.
› Verified 2 days ago
| Entity Name | Laboratory Medicine Consultants Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083675169 PECOS PAC ID: 4183617533 Enrollment ID: O20040618000578 |
News Archive
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.
InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax's activities.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather Gridley, MD 7455 W Washington Ave Ste 301, Las Vegas, NV 89128-4340 Ph: (877) 562-5227 | Heather Gridley, MD 7455 W Washington Ave Ste 301, Las Vegas, NV 89128-4340 Ph: (877) 562-5227 |
News Archive
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.
InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax's activities.
› Verified 2 days ago
Mrs. June Durkee Sigman, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 7455 W Washington Ave Ste 301, Las Vegas, NV 89128 Phone: 877-562-5227 Fax: 702-732-2310 | |
Dr. Bert G. Dougherty, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy, 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Dr. David Patrick Marmaduke, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy Ste 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Narciss Mobini, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4230 Burnham Ave, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 | |
Mr. Jonathan Howard Hughes, MD PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3059 S Maryland Pkwy Ste 100, Las Vegas, NV 89109 Phone: 702-732-3441 Fax: 702-732-2310 | |
Peter Aylward Scully, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4230 Burnham Avenue, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 | |
Jonathan Stuart Strauss, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4230 Burnham Ave, Las Vegas, NV 89119 Phone: 702-733-7866 Fax: 702-792-1319 |